We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 504

Biosimilar monoclonal antibodies emerge from the pipeline on both sides of the Atlantic

  • Bereskin & Parr LLP
  • -
  • Canada, European Union
  • -
  • March 7 2014

The European Medicines Agency ("EMEA") made its biosimilar monoclonal antibody guidelines effective in December 20121. Less than a year later, in

Methods of medical treatment and dosage claims

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • June 28 2011

In Canada, claims to methods of medical treatment are considered to fall outside the definition of invention according to section 2 of the Patent Act and a decision of the Supreme Court of Canada

Teva v Pfizer, or the “Viagra saga”: if there is no quid proper disclosure there can be no quo exclusive monopoly rights

  • Fasken Martineau DuMoulin LLP
  • -
  • Canada
  • -
  • November 19 2012

Sildenafil is the active ingredient in Viagra, the blockbuster potency-enhancing drug marketed by Pfizer

Reply affidavits allowed when new documents introduced in responding evidence

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 9 2014

In this case, there is a partial reversal of evidence. Apotex brought a motion for leave to file reply evidence. Allergan did not oppose parts of the

Canadian patent term extension is coming

  • Bereskin & Parr LLP
  • -
  • Canada, European Union
  • -
  • October 18 2013

Canada and Europe announced an agreement in principle on a Comprehensive Economic and Trade Agreement (“CETA”) that will potentially increase Canadian

Federal Court grants injunction that allows infringing biologic drug to stay on the market

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • June 20 2014

Case: AbbVie Corporation, AbbVie Deutschland GMBH & Co. KG and AbbVie Biotechnology Ltd. v. Janssen Inc., 2014 FC 489 Drug: Ustekinumab (STELARA®

The Myriad decision: what is the impact?

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • June 20 2013

As we reported in our previous article, the Supreme Court of the United States issued its long awaited decision in the Myriad case on June 13, 2013

New guideposts for the fact-intensive hypothetical world of generic damages claims

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • June 14 2014

The past year has seen significant evolution in the Canadian law of generic pharmaceutical damages claims under section 8 of the Patented Medicines

What is the threshold for the materiality of an untrue allegation in a patent?

  • Heenan Blaikie LLP
  • -
  • Canada
  • -
  • October 5 2010

In Novo Nordisk Canada Inc. v. Cobalt Pharmaceuticals Inc., 2010 FC 746., Justice Mactavish dismissed an application by Novo Nordisk Canada Inc. (“Novo Nordisk”) under the Patented Medicines (Notice of Compliance) Regulations for an order prohibiting the Minister of Health from issuing a Notice of Compliance to Cobalt Pharmaceuticals Inc. (“Cobalt”) for its generic version of repaglinide, a drug used in the treatment of Type 2 diabetes

Supreme Court of Canada: VIAGRA patent "void" for insufficient disclosure

  • Smart & Biggar/Fetherstonhaugh
  • -
  • Canada
  • -
  • November 8 2012

The Supreme Court of Canada today released the hotly anticipated decision in Teva Canada Limited v Pfizer Canada Inc, 2012 SCC 60 (sildenafil, VIAGRA